Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo inhaler Clear all

Conditions: Altitude Edema
Interventions: Advair HFA, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®); Drug
Lead sponsor: Lupin, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 34
States / cities: Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium, Umeclidinium matching placebo, Tiotropium, Tiotropium matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,017 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Asthma
Interventions: Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 56
States / cities: Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Placebo matching Olodaterol, Olodaterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 94
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more

Conditions: Bronchial Asthma
Interventions: Fluticasone propionate/salmeterol 100/50 µg, Placebo, Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT; Drug · Other
Lead sponsor: Cipla Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Covid19
Interventions: Fluticasone, Placebo; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 1,407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 87
States / cities: Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg); Drug
Lead sponsor: PhenoNet, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more

Conditions: Asthma Placebo Effects
Interventions: albuterol, placebo inhaler, placebo acupuncture; Drug · Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, VI, UMEC, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more

Conditions: Asthma
Interventions: Albuterol MDPI, Placebo, ProAir HFA inhaler; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 51
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 45 more

Conditions: Sickle Cell Disease
Interventions: Mometasone Furoate, Placebo; Drug
Lead sponsor: Jeffrey Glassberg; Other
Eligibility: 15 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: 40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo; Drug
Lead sponsor: Biota Scientific Management Pty Ltd; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 70
States / cities: Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more

Conditions: Asthma
Interventions: Lebrikizumab, Placebo, Standard of Care; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 16
States / cities: Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo ELLIPTA device, Placebo capsules for use in HANDIHALER device, Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 22
States / cities: Glendale, Arizona • Clearwater, Florida • Orlando, Florida + 19 more

Conditions: Asthma
Interventions: tiotropium-bromide, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Year to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more

Conditions: Asthma
Interventions: ELLIPTA DPI, GSK MDI, AZ MDI; Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more

Conditions: Persistent Asthma
Interventions: Beclomethasone dipropionate breath-actuated inhaler, Placebo breath-actuated inhaler, albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Huntington Beach, California • Mission Viejo, California • Orange, California + 41 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more

Conditions: Asthma
Interventions: Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more

Conditions: COPD Patients
Interventions: Symbicort, Formoterol turbohaler, Placebo for Symbicort pMDI, Placebo for Formoterol Turbohaler; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 95 Years
Enrollment: 2,026 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 224
States / cities: Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,042 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Birmingham, Alabama • Montgomery, Alabama • Mesa, Arizona + 60 more

Conditions: Bronchial Asthma
Interventions: 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product, Placebo; Drug
Lead sponsor: Cipla Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

Advair HFA in Healthy and HAPE Predisposed Subjects

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

Characterization of Placebo Responses in Stable Asthma

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Efficacy and Safety Study in Subjects With Asthma

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma